A compound chimeric antigen receptor strategy for targeting multiple myeloma.

Leukemia · 2018 · PMC5808076 · PMID 28951562

Europe PMC DOI

hedged sentence

0.0003

closest p · 0.0× alpha

0.0003

boldest claim

The sentences

highly significantP <0.0003actually significant

There were highly significant differences ( P <0.0003) in tumor burden between the control group and the BC1cCAR treatment group from day 6 onwards ( Figure 6b ).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.